Oryzon Genomics SA
MAD:ORY
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| ES |
|
Oryzon Genomics SA
MAD:ORY
|
236.8m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
72.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
